DAX19.884 ±0,0%ESt504.860 -0,1%Top 10 Crypto14,63 -3,6%Dow42.528 -0,7%Nas19.525 -0,2%Bitcoin90.115 -1,1%Euro1,0390 -0,4%Öl72,35 -0,9%Gold2.612 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Novo Nordisk A3EU6F Volkswagen (VW) vz. 766403 Tesla A1CX3T Rheinmetall 703000 Palantir A2QA4J Bayer BAY001 Amazon 906866 Mercedes-Benz Group (ex Daimler) 710000 Apple 865985 MicroStrategy 722713 Siemens Energy ENER6Y TUI TUAG50 Allianz 840400 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Ruhiger Wochenauftakt: DAX wenig bewegt -- Wall Street uneinheitlich -- VW: Einigung im Tarifkonflikt -- BMW: Unregelmäßigkeiten bei Autoexporten -- Mercedes-Benz, BVB, AstraZeneca im Fokus
Top News
Dow Jones 30 Industrial-Wert Walt Disney-Aktie: So viel Verlust hätte eine Investition in Walt Disney von vor 3 Jahren bedeutet Dow Jones 30 Industrial-Wert Walt Disney-Aktie: So viel Verlust hätte eine Investition in Walt Disney von vor 3 Jahren bedeutet
NASDAQ Composite Index-Titel Intel-Aktie: So viel Verlust hätte eine Intel-Investition von vor 10 Jahren eingebracht NASDAQ Composite Index-Titel Intel-Aktie: So viel Verlust hätte eine Intel-Investition von vor 10 Jahren eingebracht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

I-MAB (spons. ADRs) Aktie

NeuKaufenVerkaufen
0,8800 EUR -0,0150 EUR -1,68 %
FSE
0,9531 USD +0,0035 USD +0,37 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone
Div. Rendite0,00%

WKNA2PVC6

ISINUS44975P1030

SymbolIMAB

I-MAB (spons. ADRs) Aktien News

DatumMeistgelesen
PR NewswireI-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
PR NewswireI-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
PR NewswireI-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
PR NewswireI-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
PR NewswireI-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022
PR NewswireI-Mab Announces Share Purchase Plans by the Company and the Senior Management
PR NewswireI-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
PR NewswireI-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
PR NewswireI-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
PR NewswireI-Mab to Host 2022 R&D Day
PR NewswireI-Mab Receives Top Rankings in Five Categories by Institutional Investor
PR NewswireI-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
PR NewswireI-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
PR NewswireI-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
PR NewswireI-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
PR NewswireI-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
PR NewswireI-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
PR NewswireI-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
PR NewswireI-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
PR NewswireI-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
PR NewswireI-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
PR NewswireI-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
PR NewswireI-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
PR NewswireI-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
PR NewswireI-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
PR NewswireI-Mab Announces Execution of Senior Management Team Share Purchase Plan
PR NewswireI-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
PR NewswireI-Mab Announces Senior Management Team Share Purchase Plan
PR NewswireI-Mab Announces Upcoming Participation at January Conferences
PR NewswireI-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

I-MAB (spons. ADRs) News

I-MAB (spons. ADRs) News: auf dieser Seite finden Sie alle I-MAB (spons. ADRs) News und Nachrichten zur I-MAB (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch I-MAB (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um I-MAB (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.